Peter Kosek, MD
Interventional Pain Medicine · Springfield, ORNPI 1639120801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Nevro Corp. accounts for 70.2% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for interventional pain medicine clinicians in OR, where the typical reported total is $8,094.
Across 13 payments — averaging $30.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$277
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
- AbbVie$36
- Collegium Pharmaceutical, Inc.$22
Across 64 payments — averaging $10,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$634K
- Boston Scientific$14K
What the payments were for
- Food & beverage$395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 10 | $277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $59 |
| AbbVie | 1 | $36 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
How this compares
$395 in reported general payments places this provider in the 10th percentile of 22 interventional pain medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine Hcl | 513 | $16,426 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $4,495 |
| Aripiprazole | 99 | $2,821 |
| Duloxetine Hcl | 194 | $2,754 |
| Lamotrigine | 124 | $1,137 |
| Olanzapine | 63 | $936 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $867 |
| Naltrexone Hcl | 30 | $797 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 19 | $628 |
| Oxycodone Hcl | 22 | $322 |
| Gabapentin | 25 | $294 |
| Tizanidine Hcl | 18 | $218 |
| Pregabalin | 12 | $184 |
| Guanfacine Hcl | 11 | $181 |
| Pantoprazole Sodium | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Springfield
- Gregory MooreEugene$377K
- Gregory PhillipsEugene$50K
- Stephen PeirceEugene$28K
- Rishi VoraEugene$16K
- George JohnstonMedford$14K
- Poly ChenSalem$14K
- Kwo Wei HoTigard$13K
- Carl BalogPortland$12K
- Joseph DunnEugene$10K
- Donna MorganEugene$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.